Scarica l'app Stockscreener
25.43
1.56%
0.39
Dopo l'orario di chiusura:
25.08
-0.35
-1.38%
Precedente Chiudi:
$25.04
Aprire:
$25.15
Volume 24 ore:
756.48K
Relative Volume:
1.17
Capitalizzazione di mercato:
$1.80B
Reddito:
$80.89M
Utile/perdita netta:
$-144.73M
Rapporto P/E:
-8.5623
EPS:
-2.97
Flusso di cassa netto:
$-83.87M
1 W Prestazione:
+0.91%
1M Prestazione:
+14.55%
6M Prestazione:
+98.98%
1 anno Prestazione:
+293.65%
Intervallo 1D:
$23.89
$25.46
Intervallo di 1 settimana:
$23.51
$25.46
Portata 52W:
$4.96
$27.60
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com
(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India
Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India
Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com
Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com
Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia
Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 - Investing.com India
UBS sees upside for Nurix stock driven by promising NX-5948 data in CLL/SLL - Investing.com India
UBS Group Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
What is HC Wainwright’s Forecast for NRIX FY2024 Earnings? - Defense World
(NRIX) On The My Stocks Page - Stock Traders Daily
HC Wainwright Has Bullish Estimate for NRIX FY2024 Earnings - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Rating Reaffirmed by Needham & Company LLC - Defense World
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit - The Manila Times
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial - Clinical Trials Arena
WestHill Financial Advisors Inc. Sells 45,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Presents Positive Results from the - GlobeNewswire
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia - Yahoo Finance
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia - The Manila Times
Nurix Therapeutics stock soars to 52-week high of $26.31 By Investing.com - Investing.com South Africa
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.31 - Investing.com
The Manufacturers Life Insurance Company Purchases 4,583 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics adds pharma veteran Anil Kapur to board - Investing.com
Nurix Therapeutics adds pharma veteran Anil Kapur to board By Investing.com - Investing.com South Africa
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - GlobeNewswire
Take off with Nurix Therapeutics Inc (NRIX): Get ready for trading - SETE News
SG Americas Securities LLC Sells 80,254 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - Defense World
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nurix Therapeutics Inc Azioni (NRIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Nov 04 '24 |
Sale |
25.00 |
3,290 |
82,250 |
28,084 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):